Search results
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 2 hours agoRapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of NTLA-2001 for the treatment of hereditary ATTR
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
Zacks via Yahoo Finance· 23 hours agoBeam Therapeutics is also developing an in vivo base editor BEAM-302 for the treatment of alpha-1...
Yes, adults can develop food allergies—here are four types you need to know about
Medical Xpress· 22 hours agoPreschoolers are about four times more likely to have a food allergy than adults and are more likely...
Saylor predicts SEC will designate Ethereum as a security and deny spot ETF applications this summer
CryptoSlate· 7 days agoMicroStrategy executive chairman and co-founder Michael Saylor believes the SEC will classify...
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
Zacks via Yahoo Finance· 2 days agoVertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of...
'An Officer and a Gentleman' actor Louis Gossett Jr. died from COPD, report says: What to know about...
Yahoo Canada Style· 7 days ago(Photo via Getty Images) Catherine Falls Commercial via Getty Images Who is at risk...
Chain of Alliance Beta Release Now Live By Chainwire
Investing.com· 2 days agoChain of Alliance Beta Release Now Live
How Moderna's cost-cutting moves hit a Bay Area biotech - San Francisco Business Times
The Business Journals· 7 days agoAs Moderna Inc. works toward expanding its approved products beyond its Covid-19 vaccine, the...
Revenge of the Fifth news - XWVM mod for STAR WARS™ - X-Wing Special Edition
Mod DB· 4 days agoThe Emperor is most displeased at the proliferation of Rebel propaganda centred around a project...
Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview
GuruFocus.com via Yahoo Finance· 2 days agoThe company also received clearance for its BEAM-302 program in the UK and is on track to initiate a Phase 1/2 trial for alpha-1 antitrypsin deficiency ...
